Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib + Dabrafenib + Trametinib in BRAF-mutant Melanoma
NCT03272464Phase 1Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in melanoma and solid tumor, sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 2 months. Started May 2019; status: terminated.
02
Drugs
itacitinib
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT03272464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272464.